Brief: Adc Therapeutics Says Announced Exclusive License With Mitsubishi Tanabe Pharma Corporation To Develop And Commercialize Zynlonta® In Japan
18/01/2022 10:09
Jan 18 (Reuters) -
* ADC THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE WITH
MITSUBISHI
TANABE PHARMA CORPORATION TO DEVELOP AND COMMERCIALIZE ZYNLONTA®
(LONCASTUXIMAB TESIRINE-LPYL) IN JAPAN
Source text for Eikon: ID:nBw66rZ5pa
Further company coverage: ADCT.N
((reuters.briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million